Antipyrine

Fever is one of the most common clinical symptoms, and antipyretic and analgesic drugs are the core medication category for relieving such symptoms. Phenazone is a classic pyrazolone derivative among them. It works by inhibiting the synthesis and release of prostaglandins in the hypothalamic thermoregulatory center, dilating peripheral blood vessels and increasing sweating to accelerate heat dissipation. Meanwhile, it can also inhibit the synthesis of prostaglandins in inflamed local areas to exert an analgesic effect. Phenazone is mostly used for urgent antipyretic treatment in cases of acute high fever, and can also relieve mild to moderate pain such as headache, neuralgia, muscle pain and rheumatic pain. It is one of the commonly used basic drugs for the symptomatic treatment of fever and pain.

As a classic antipyretic and analgesic that has been on the market for more than a hundred years, phenazone currently has a global market size of approximately USD 120 million, maintaining a steady low growth rate of around 2% overall. Since its patent has expired for decades, the global market is dominated by generic drug supplies. China and India are the world's most important API production regions, accounting for more than 85% of the global production capacity combined. Domestically, phenazone is included in the Class A catalog of medical insurance, with stable demand from primary medical terminals. Currently, there are more than 30 approved preparation approval numbers in China, with sufficient API supply and a relatively fragmented market competition pattern.

Phenazone was originally developed by Bayer AG of Germany, with the trade name Phenazone. Its core compound patent expired as early as the end of the 19th century, and there are currently no valid patent restrictions. The mainstream dosage forms on the market include tablets, injections and external nasal drops. Common specifications are 0.1g and 0.3g for tablets, and 2ml:0.2g for injections, etc. The original research product of this variety has not been marketed in China, and domestic reference preparations are mostly generic approved products of the same variety included in the *Reference Preparation Catalog for Chemical Generic Drugs*. Currently, there are a total of 6 domestic enterprises whose phenazone APIs have completed registration with the CDE and obtained Class A status, corresponding to a total of 32 approval numbers for approved oral and injectable preparations. (Data as of November 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of phenazone impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products fully comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully support pharmaceutical enterprises' needs in the whole process of API R&D, quality research and production quality control.